Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B

J Am Acad Dermatol. 2018 Jun;78(6):1205-1207.e1. doi: 10.1016/j.jaad.2018.02.023. Epub 2018 Feb 10.

Authors

Deep Joshipura¹, Abdulaziz Alomran¹, Pedro Zancanaro¹, David Rosmarin²

Affiliations

¹ Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.
² Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. Electronic address: drosmarin@tuftsmedicalcenter.org.

PMID: 29438765
DOI: 10.1016/j.jaad.2018.02.023

No abstract available

Publication types

Clinical Trial

MeSH terms

Administration, Topical
Adult
Combined Modality Therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Janus Kinases / antagonists & inhibitors
Male
Middle Aged
Nitriles
Prospective Studies
Pyrazoles / therapeutic use*
Pyrimidines
Risk Assessment
Severity of Illness Index
Time Factors
Treatment Outcome
Ultraviolet Therapy / methods*
Vitiligo / diagnosis
Vitiligo / drug therapy*
Vitiligo / radiotherapy*

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
Janus Kinases